Velocity Clinical Research Executive and Leadership Team

George Carey, the Chief Executive Officer at Velocity Clinical Research, directs the overarching strategic vision for the organization. By aligning site capabilities with the needs of global biopharmaceutical partners, Carey ensures the company maintains a competitive edge in the clinical trial landscape. This leadership role involves constant evaluation of market trends to optimize patient recruitment and trial efficiency. George Carey drives the expansion of the integrated site network, fostering partnerships that accelerate drug development timelines. Through rigorous oversight of corporate objectives, the Chief Executive Officer maintains high standards of operational excellence across all North American facilities. Carey prioritizes the integration of advanced research methodologies to support complex study requirements. By championing innovation in site management, the Chief Executive Officer secures the long-term growth of the organization while delivering consistent value to contract research organization customers and stakeholders alike.

Mike Zaranek, the Chief Financial Officer at Velocity Clinical Research, manages the fiscal health and capital allocation strategies for the enterprise. Overseeing financial planning and analysis, the Chief Financial Officer ensures that resource distribution supports the rapid scaling of clinical trial sites. This role involves managing complex budgetary requirements for multi-site operations across the United States. Mike Zaranek drives financial transparency and reporting accuracy, providing the board with critical insights into revenue growth and operational expenditures. By optimizing the cost structure of clinical research activities, Zaranek enables the organization to invest in cutting-edge site infrastructure. The Chief Financial Officer collaborates with executive leadership to assess the financial viability of new market entries and strategic acquisitions. Through disciplined fiscal management, Zaranek secures the capital necessary to sustain the company's position as a leader in the integrated site organization sector.

Robert Buynak, the Physician and President at Velocity Clinical Research, provides medical leadership and strategic direction for the organization's research portfolio. Overseeing the clinical integrity of trial protocols, the Physician and President ensures that all site activities meet the highest standards of medical ethics and patient safety. This role involves bridging the gap between complex scientific requirements and practical site execution. Robert Buynak drives the development of medical expertise within the organization, guiding research teams through the intricacies of diverse therapeutic areas. By collaborating with biopharmaceutical sponsors, Buynak ensures that trial designs are optimized for successful patient recruitment and data collection. The Physician and President maintains oversight of medical quality assurance, ensuring that every study conducted at the company's sites yields reliable results. Through clinical leadership, Buynak advances the company's mission to accelerate the delivery of new treatments to patients.

Brandi Lang, the Chief Legal Officer at Velocity Clinical Research, architects the regulatory and compliance framework governing all clinical trial operations. Managing complex legal risks, the Chief Legal Officer ensures that site activities adhere to stringent federal and international research standards. This role involves drafting and negotiating critical contracts with biopharmaceutical partners and contract research organizations. Brandi Lang drives the development of internal policies that protect the integrity of clinical data and patient privacy. By overseeing corporate governance, Lang mitigates potential liabilities associated with large-scale medical research. The Chief Legal Officer works closely with the executive team to navigate the evolving regulatory landscape, ensuring that all operational expansions remain compliant with industry mandates. Through proactive legal strategy, Lang safeguards the reputation of the organization while facilitating seamless collaboration between research sites and external sponsors.

Nicholas Spittal, the Chief Operations Officer at Velocity Clinical Research, executes the daily operational strategy across the entire network of clinical trial sites. Overseeing site performance and patient recruitment workflows, the Chief Operations Officer ensures that every facility meets the high-volume demands of biopharmaceutical customers. This role involves standardizing operational procedures to maximize efficiency and data quality. Nicholas Spittal drives the implementation of new technologies that streamline trial execution and improve site productivity. By managing the logistics of multi-site operations, Spittal ensures that research teams have the necessary resources to meet study milestones. The Chief Operations Officer collaborates with the executive leadership to scale site capabilities in response to market demand. Through rigorous process optimization, Spittal maintains the operational agility required to support diverse clinical research programs across the country.

Kimberly Ballard, the Chief People Officer at Velocity Clinical Research, directs the human capital strategy and organizational culture initiatives. Overseeing talent acquisition and employee development, the Chief People Officer ensures that the company attracts and retains top-tier clinical research professionals. This role involves designing programs that foster professional growth and maintain high engagement levels across the national site network. Kimberly Ballard drives the implementation of performance management systems that align individual contributions with the company's mission of accelerating medical breakthroughs. By cultivating a diverse and inclusive workplace, Ballard strengthens the organizational foundation necessary for complex clinical operations. The Chief People Officer works with the executive team to address workforce planning needs as the company expands its footprint. Through strategic talent management, Ballard ensures that the organization possesses the expertise required to deliver superior results for biopharmaceutical partners.